Expert Interview
Discussing GRAIL's Landmark NHS-Galleri Trial for their Galleri® Multi-Cancer Early Detection (MCED) Blood Test for Population Cancer Screening
Ticker(s): GRAL, GH, EXAS, NTRAInstitution: Oncology Institute
- Board-certified Oncologist practicing medicine at the Oncology Institute of Hope and Innovation
- Manages 100 patients who are diagnosed with late-stage cancers per year
- Prior Medical Director for Oncology/Hematology for Kaiser Permanente in San Diego; Former Medical Director for Hematology / Oncology at Quest Diagnostics and Chief Medical Officer for Agendia and Signal Genetics; and is a Special Consultant to the FDA on medical devices and multi-analyte testing
How many patients do you screen for cancer?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Blood Test for Population Cancer Screening?
Added By: lilly_adminHow do you see the future of Grail's Galleri test evolving?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
